Researchers at The University of Texas Health Science Center Receive Grant To Evaluate Psychedelics | Cannabis Law Report | Where to order Skittles Moonrock online

Learn how to order marijuana online. TOP QUALITY GRADE A++

Cannabyss Inc. is the best place online to buy top quality weed, cannabis, vape, marijuana and CBD products. Get your borderless orders delivered at the pickup spot with ease. Top Grade products for client satisfaction.

👉 Click here to Visit our shop! 🛒

Researchers at The University of Texas Health Science Center at San Antonio and their collaborators at Emory University have received a $4.9 million grant aimed at significantly improving treatment and recovery rates for individuals suffering from post-traumatic stress disorder.

The project was recently selected for funding by the U.S. Department of Defense through a call for studies to evaluate psychedelics as a treatment for PTSD in hopes of pushing the field forward. In this effort, the innovative clinical trial will use 3,4-methylenedioxy-methamphetamine hydrochloride, or MDMA, commonly known as ecstasy, in combination with a leading psychotherapy for PTSD called Prolonged Exposure.

Prolonged Exposure therapy for PTSD works by helping individuals process traumatic memories and feelings while recalling them in a safe environment. The goal of the new study is to capitalize on beneficial MDMA properties in a synergistic way to enhance Prolonged Exposure’s efficacy, hopefully leading to greater symptom reductions and more patients being treated into remission.

The trial’s lead investigator is Alan Peterson, PhD, professor of psychiatry and behavioral sciences at UT Health San Antonio and director of the STRONG STAR Consortium. STRONG STAR is a national research network focused on finding the best preventions and treatments for psychological health issues affecting military members, veterans, and first responders.

“Cognitive-behavioral psychotherapies have the strongest scientific support for the treatment of PTSD, but for military service members and veterans, recovery rates with these treatments seem to have maximized at about 50%,” Peterson said. “Existing medications have not shown good promise when used alone, so we’re looking at novel ways to enhance treatment outcomes so that more of our psychologically wounded warfighters have the chance of full recovery from PTSD.”

Researchers believe MDMA shows some of the greatest potential in this regard. One reason is that MDMA, in combination with psychotherapy, has demonstrated significant improvements in PTSD. It has revealed increased neuroplasticity, or the brain’s ability to adapt, for about two weeks after administration, which is beneficial for therapeutic learning.

Finally, it impacts emotional memory circuits related to PTSD development and recovery. These memory circuits affect conditioned fear responses that are associated with PTSD. Researchers think MDMA will work synergistically with Prolonged Exposure to help patients process traumatic memories.

Other research support for MDMA comes from study collaborators at Emory University School of Medicine, who include Jessica Maples-Keller, PhD, Barbara Rothbaum, PhD, and Boadie Dunlop, MD.

In an ongoing, open-label pilot study by the Emory Healthcare Veterans Program, results show that one dose of MDMA significantly reduces PTSD symptoms among military members and veterans when combined with massed Prolonged Exposure (PE). In massed PE, therapy is delivered daily for two weeks instead of the standard once or twice weekly over several weeks or months, coinciding with the timeline of MDMA’s therapeutic effects on neuroplasticity.

Learn more at

Researchers to test psychedelic drug plus therapy to help military members with PTSD